CBX-12

• Cybrexa Therapeutics presented new preclinical data at ESMO TAT 2025 demonstrating their alphalex™ peptide-drug conjugates selectively deliver microtubule inhibitors to tumor cells while sparing healthy tissue. • Unlike antibody-drug conjugates, the alphalex™ platform uses a pH-driven targeting approach that exploits tumor acidity, potentially overcoming limitations of antigen-based therapies for hard-to-treat solid tumors. • Preclinical studies showed complete tumor suppression in colorectal cancer models as monotherapy, with synergistic effects when combined with doxorubicin and anti-PD-L1 therapy in various cancer models.

Seraxis received FDA IND allowance for SR-02, a stem cell-derived islet replacement therapy, marking a potential functional cure for insulin-requiring diabetes.

Cybrexa Therapeutics initiated a Phase 2 clinical trial of CBX-12, a peptide-drug conjugate, in patients with platinum-resistant or refractory ovarian cancer.